News

The phase III DURATION-8 trial showed that Bydureon, taken just once a week in combination with Forxiga once daily significantly reduced blood sugar, compared with the individual medicines

The offering was upsized by $25 million over the offering amount anticipated to be sold as previously announced. This is in addition to $50 million raised separately through

Under the terms of the collaboration, Dr. Reddy’s will commercialise XGEVA (denosumab), Vectibix (panitumumab) and Prolia (denosumab) in India. In 2015, Dr. Reddy’s announced an initial strategic collaboration with Amgen to

Under the license, TeneoBio will be able to use the OmniFlic technology from the OmniAb platform to discover fully human bispecific antibodies to be developed for the treatment of various

The CHMP adopted a positive opinion recommending approval of Pfizer's Ibrance (palbociclib) in combination with endocrine therapy to treat HR-positive, HER2-negative metastatic breast cancer. Its opinion specifies that

In the Resolve phase 3 trial of 11,856 older adults (60 years of age and older), the vaccine did not meet its efficacy goals, including the primary objective

Paul Foster, M.D., chief medical officer at Xencor, said: "A previously completed Phase 1a study of intravenous administration of XmAb7195 has shown potent suppression of IgE, in particular demonstrating

YOSPRALA is indicated for patients who require aspirin for secondary prevention of cardiovascular (CV) and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers.

The drug was studied in patients with type 2 diabetes (T2D) in combination with sitagliptin and metformin. The double-blind, placebo-controlled phase 3 VERTIS SITA2 trial randomized 463 subjects